{"id":47950,"date":"2022-09-05T01:04:18","date_gmt":"2022-09-04T23:04:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/"},"modified":"2022-09-05T01:04:18","modified_gmt":"2022-09-04T23:04:18","slug":"wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/","title":{"rendered":"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022"},"content":{"rendered":"<div>\n<p>ST. LOUIS &amp; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwugen.com%2F&amp;esheet=52843845&amp;newsitemid=20220904005001&amp;lan=en-US&amp;anchor=Wugen%2C+Inc.&amp;index=1&amp;md5=c130ab4f8c88359d4075644e93493dd4\" rel=\"nofollow noopener\" shape=\"rect\">Wugen, Inc.<\/a>, a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on WU-NK-101, the company\u2019s lead memory natural killer (NK) cell therapy product, at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris, France from September 9-13, 2022.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220904005001\/en\/1128237\/5\/WUGEN-Logo-White-Background-FIN_copy.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220904005001\/en\/1128237\/21\/WUGEN-Logo-White-Background-FIN_copy.jpg\"><\/a><\/p>\n<p>\nThe results highlight key features of WU-NK-101\u2019s unique cytokine-induced memory-like (CIML) phenotype and support its clinical development for solid tumors. The data reinforced key phenotypic characteristics of WU-NK-101, including its potent anti-tumor cytotoxicity and enhanced metabolic fitness that supports resilience within the immunosuppressive solid tumor microenvironment (TME). Additionally, when used in combination with monoclonal antibodies (mAbs), in preclinical models, WU-NK-101 demonstrated further enhanced anti-tumor activity, with robust tumor penetration and persistence.\n<\/p>\n<p>\nThe details of Wugen\u2019s presentation at ESMO are as follows:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Title:<\/b> WU-NK-101: An Enhanced NK Cell Therapy Optimized for Function in the Tumor Microenvironment (TME)\n<\/li>\n<li>\n<b>Abstract Number:<\/b> 11P\n<\/li>\n<li>\n<b>Date and time:<\/b> Sunday, September 11, 2022, from 12:00 \u2013 13:00 CEST (6:00 \u2013 7:00 a.m. EDT)\n<\/li>\n<li>\n<b>Location:<\/b> Paris Expo Porte De Versailles, Poster Area, Hall 4\n<\/li>\n<\/ul>\n<p>\nAdditional meeting information can be found at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.esmo.org%2F&amp;esheet=52843845&amp;newsitemid=20220904005001&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.esmo.org%2F&amp;index=2&amp;md5=d90dc0d923c7c6c42f18660da928cae7\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.esmo.org\/<\/a>.\n<\/p>\n<p>\n<b>About WU-NK-101<\/b>\n<\/p>\n<p>\nWU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary Moneta\u2122 platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.\n<\/p>\n<p>\n<b>About Wugen<\/b>\n<\/p>\n<p>\nWugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta\u2122 platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam12.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.wugen.com%252F%26data%3D04%257C01%257CElsie.Yau%2540sternir.com%257C11de7373b9054c35f8c408da03761fb6%257Cb71ff3f628164ca8a9b938f820f91ad1%257C0%257C0%257C637826103122763870%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C3000%26sdata%3D1xyoJbS0SUWXVliTIDlMdM5%252BSvr9NxVBj19px%252BK%252Bg50%253D%26reserved%3D0&amp;esheet=52843845&amp;newsitemid=20220904005001&amp;lan=en-US&amp;anchor=www.wugen.com&amp;index=3&amp;md5=cd0d15aa00b52e55bf9cde426fe7b002\" rel=\"nofollow noopener\" shape=\"rect\">www.wugen.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investors:<\/b><br \/>Elsie Yau, Stern Investor Relations, Inc.<br \/>\n<br \/>212-698-8700<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#58;&#101;&#108;&#115;ie&#46;y&#x61;&#x75;&#x40;&#x73;&#x74;&#x65;&#114;&#110;&#105;&#114;&#46;com\" rel=\"nofollow noopener\" shape=\"rect\">elsie&#46;&#121;&#97;&#117;&#64;&#115;&#116;&#101;&#x72;&#x6e;&#x69;&#x72;&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>ST. LOUIS &amp; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on WU-NK-101, the company\u2019s lead memory natural killer (NK) cell therapy product, at the European Society for Medical Oncology &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-47950","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ST. LOUIS &amp; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on WU-NK-101, the company\u2019s lead memory natural killer (NK) cell therapy product, at the European Society for Medical Oncology ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-04T23:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220904005001\/en\/1128237\/21\/WUGEN-Logo-White-Background-FIN_copy.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022\",\"datePublished\":\"2022-09-04T23:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/\"},\"wordCount\":390,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220904005001\\\/en\\\/1128237\\\/21\\\/WUGEN-Logo-White-Background-FIN_copy.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/\",\"name\":\"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220904005001\\\/en\\\/1128237\\\/21\\\/WUGEN-Logo-White-Background-FIN_copy.jpg\",\"datePublished\":\"2022-09-04T23:04:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220904005001\\\/en\\\/1128237\\\/21\\\/WUGEN-Logo-White-Background-FIN_copy.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220904005001\\\/en\\\/1128237\\\/21\\\/WUGEN-Logo-White-Background-FIN_copy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/","og_locale":"en_US","og_type":"article","og_title":"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend","og_description":"ST. LOUIS &amp; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on WU-NK-101, the company\u2019s lead memory natural killer (NK) cell therapy product, at the European Society for Medical Oncology ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-04T23:04:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220904005001\/en\/1128237\/21\/WUGEN-Logo-White-Background-FIN_copy.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022","datePublished":"2022-09-04T23:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/"},"wordCount":390,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220904005001\/en\/1128237\/21\/WUGEN-Logo-White-Background-FIN_copy.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/","url":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/","name":"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220904005001\/en\/1128237\/21\/WUGEN-Logo-White-Background-FIN_copy.jpg","datePublished":"2022-09-04T23:04:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220904005001\/en\/1128237\/21\/WUGEN-Logo-White-Background-FIN_copy.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220904005001\/en\/1128237\/21\/WUGEN-Logo-White-Background-FIN_copy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/wugen-announces-presentation-of-wu-nk-101-preclinical-data-at-the-european-society-for-medical-oncology-esmo-congress-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47950"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47950\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}